- Home
- » Tags
- » Mifamurtide
Top View
- MEPACT® Prescribing Information
- (INN) for Biological and Biotechnological Substances
- Access to Cancer Medicines in Europe: an Analysis of Existing Challenges and Countries’ Responses
- Estonian Statistics on Medicines 2014
- Advances on the Formulation of Proteins Using Nanotechnologies
- Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection
- List Item Minutes of the PRAC Meeting 6-9 October 2014
- Mifamurtide and TAM-Like Macrophages: Effect on Proliferation, Migration and Differentiation of Osteosarcoma Cells
- NICE Tas RFL Formulary Sept 2016
- Future Directions in the Treatment of Osteosarcoma
- Microencapsulated Lipid Nanoparticles for Pulmonary Delivery of Biopharmaceutical Agents
- Vaccine Efficacy Against Primary and Metastatic Cancer with in Vitro-Generated CD103+ Conventional Dendritic Cells
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Who Drug Information
- Repurposing Drugs for COVID-19 Based on Transcriptional Response of Host Cells to SARS-Cov-2
- Nanotechnology As a Platform for the Development of Injectable Parenteral Formulations: a Comprehensive Review of the Know-Hows and State of the Art
- Pharmaabkommen A1 E
- ABSTRACT BOOK 18Th Congress of the EAHP, 13-15 March 2013, Paris, France March 2013
- Advancements and Technologies Driving Peptide Drug Design and Development
- Access to Mepact® (Mifamurtide) in the United States
- An Inventory of Medicinal Products Causing Skin Rash: Clinical and Regulatory Lessons
- Therapeutic Value and Price of the New Pharmaceuticals Commercialized in Argentina: Are They Worth What They Cost?
- L-MTP-PE and Zoledronic Acid Combination In
- Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
- Advances on the Formulation of Proteins Using Nanotechnologies
- Improving Access to Cancer Care a First Analysis of Pharmaceutical Company Actions in Low- and Middle-Income Countries
- Mepact- Ct-8306
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies
- Osteosarcoma
- Pediatric Osteosarcoma: Connecting Present and Future Approaches to Diagnosis and Treatment
- Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration
- Mepact Guideline
- Progress in the Chemotherapeutic Treatment of Osteosarcoma (Review)
- Effectiveness of Mifamurtide in Addition to Standard Chemotherapy for High-Grade Osteosarcoma: a Systematic Review
- Original Article L-MTP-PE and Zoledronic Acid Combination in Osteosarcoma: Preclinical Evidence of Positive Therapeutic Combination for Clinical Transfer
- Osteosarcoma Treatment ¬タモ Where Do We Stand? a State of the Art Review
- Drug Information
- Osteosarcoma Pathogenesis Leads the Way to New Target Treatments
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- (INN) for Biological and Biotechnological Substances
- [Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
- Annals of Oncology Original Articles
- An Open Access Database of Licensed Cancer Drugs Pan Pantziarka 1,2, §, Rica Capistrano 1, Arno De Potter 3, Liese Vandeborne 1, Gauthier Bouche 1
- Medicines & Vaccines in Development for Cancer
- Development of Afatinib Lipid Nanoparticles Targeting Non Small Cell Lung Cancer
- Semi-Synthesis of Pharmaceutical Fc-Fusion Compounds: Site-Specific Bioconjugation and Applications
- Minutes of PRAC Meeting on 26-29 November 2018
- ( 12 ) United States Patent
- Concept ID Name Class 1319998 Acebutolol Adrenergics 1154343
- High-Dose Methotrexate, Doxorubicin, Cisplatin, and If
- ( 12 ) United States Patent
- Immunostimulating Agents for the Prevention of Acute Otitis Media (Protocol)
- Natural Product and Natural Product Derived Drugs in Clinical Trials